Emergence of multidrug resistant isolates and mortality predictors in patients with solid tumors or hematological malignancies

Aliye Bastug, Bircan Kayaaslan, Sumeyye Kazancioglu, Ayse But, Halide Aslaner, Esragul Akinci, Meltem Arzu Yetkin, Dilek Kanyilmaz, Selim Sirri Eren, Hurrem Bodur

Department of Infectious Diseases and Clinical Microbiology, Ankara Numune Training and Research Hospital, Ankara, Turkey

Abstract

Introduction: Infections are an important preventable cause of death in cancer patients. The aim of this study was to clarify the epidemiologic characteristics and resistance patterns of causative isolates and mortality predictors in infections of cancer patients.

Methodology: Patients with sterile site infections were evaluated in a retrospective cohort study. Etiological agents, antimicrobial resistance patterns of the isolates, and possible risk factors for mortality were recorded. Survivors and non-survivors on day 30 after each infection onset were compared to identify the predictors of mortality.

Results: A total of 205 infection episodes of 132 patients were included in this study. Of them, 75% had hematologic malignancies and 25% had solid tumors. Febrile neutropenia was diagnosed in 61.5%. Bloodstream infections were the most frequent infection (78%). The majority of the pathogens were Enterobacteriaceae (44.3%) and nonfermentative isolates (17.6%). Multidrug-resistant (MDR) infections were responsible for 40% of the episodes. The mortality rate was 23.4%. Inadequate initial antibiotic treatment (OR = 4.04, 95% CI = 1.80–9.05, p = 0.001), prolonged neutropenia (> 7 days) before infection (OR = 3.61, 95% CI = 1.48–8.80, p = 0.005), infection due to Klebsiella species (OR = 3.75, 95% CI = 1.31–10.7, p = 0.013), and Acinetobacter baumannii (OR = 5.00, 95% CI = 1.38–18.2, p = 0.014) were independent predictors of mortality.

Conclusions: Gram-negative isolates were found to be the predominant pathogens with higher mortality rates. Local epidemiological data should be taken into account when administering empirical therapy since the inadequacy of initial antibiotherapy is associated with a poor outcome.

Key words: mortality; infections; hematological malignancies; neutropenia; MDR

J Infect Dev Ctries 2015; 9(10):1100-1107. doi:10.3855/jidc.6805

(Received 25 February 2015 – Accepted 21 August 2015)

Copyright © 2015 Bastug et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Patients with hemat-oncological malignancies have a predisposition towards severe, life-threatening infections that result in prolonged hospitalization and higher mortality rates [1,2]. The majority of cancer patients harbor high risk for infections that are mostly assumed to be caused by immunosuppressive therapies [3]. Because of the high mortality rates due to infections, commencing appropriate empirical antimicrobial therapy is crucial in these patients. The causative pathogens are usually equivocal; therefore, it is important to know the local epidemiological data before starting adequate empirical antimicrobial therapy, especially in patients who are vulnerable to serious infections [4]. The epidemiological characteristics of causative isolates of bloodstream infections (BSIs) in cancer patients have changed recently, with a shift toward Gram-negative infections.

In addition, the increasing incidence rate of multidrug-resistant (MDR) microorganisms has become a major problem worldwide [3,5]. To the best of our knowledge, there exist limited data in the literature, especially from Turkey, about the epidemiology and risk factors of mortality in infected patients with hemat-oncological malignancies. Most of the available data are relevant to only bacteremic and neutropenic patients with cancer. In this study, we aimed to identify the recent epidemiology of infections and mortality risk factors in infected neutropenic and non-neutropenic patients with hemat-oncological malignancies.

Methodology

Study design, setting, and patients

This retrospective cohort study was conducted at Ankara Numune Training and Research Hospital.
in only high
growth test in accordance with CLSI
tistically and the impact of the risk
onset of
bacterial therapy
neutropenic patients.
neutropenic episodes was also evaluated, since
fluoroquinolone prophylaxis on the acquisition of
factors on mortality was defined. The effect of
laboratory characteristics of the two groups were
divided in two groups, survivors and non-
survivors, according to the outcome on day 30 after each
infection onset. The demographic, clinical, and
laboratory characteristics of the two groups were
compared statistically and the impact of the risk
factors on mortality was defined. The effect of
fluoroquinolone prophylaxis on the acquisition of
infections with MDR isolates in 126 febrile
neutropenic episodes was also evaluated, since
quinolone prophylaxis was used in only high-risk
neutropenic patients.

**Data collection**

The data were recorded for each patient during
every episode of infection and included demographics,
malignancy type, presence or absence of stem cell
transplantation, site of infection, time to the onset of
infection, presence of fever (≥ 38°C), absolute
neutrophil count, duration and severity of neutropenia,
causative isolates and their antimicrobial resistance
patterns, presence of quinolone prophylaxis for
neutropenic patients, empirical antimicrobial therapy
during the onset of infection before positive culture
results, antimicrobial therapy, length of time to
infection, and outcome on day 30 after infection onset.

**Definitions**

Definitions are provided in Table 1 according to
previous studies and guidelines [6,8-11].

**Microbiological studies**

Identification and antimicrobial susceptibility tests
of the microorganisms were performed using a VITEK
automated system (BioMerieux, Marcy l'Etoile,
France). The Clinical and Laboratory Standards
Institute (CLSI) criteria were used to determine the
resistance or susceptibility to the antimicrobial agents
[12]. Extended-spectrum beta lactamase (ESBL)
production was investigated and confirmed using a
double-disk synergy test in accordance with CLSI
guidelines [13].

**Table 1. Definitions**

| Laboratory-confirmed bloodstream infection (LCBI) [6] | Patients with at least one of the following criteria:
| --- | --- |
| 1) Isolation of microorganisms from blood (such as *S. aureus*, *Enterococcus* spp., *E. coli*, *Klebsiella* spp., *Pseudomonas* spp., *Candida* spp., and others) for ≥ 1 positive culture that was not related to an infection of other body sites; 2) Patients with one of the following signs that was not related to an infection of other body sites: fever (38°C), chills, or hypotension and ≥ 2 positive separate culture results for possible skin contaminant pathogens, such as coagulase-negative *Staphylococcus* |
| Symptomatic urinary tract infection [6] | Patients with one of the following signs with no other cause: fever (38°C), urgency, dysuria or suprapubic tenderness, and has a positive urine culture with ≥ 10^5 colony forming units (CFUs)/mL bacteria with no more than two species |
| Neutropenia [8] | Absolute neutrophil count (ANC) of < 500 cells/mm³ or ANC which was expected to decrease to < 500 cells/mm³ during the next 48 hours |
| Prolonged neutropenia [8] | ANC < 500 cells/mm³ for > 7 days |
| Profound neutropenia [8] | ANC < 100 cells/mm³ |
| Febrile neutropenia [8] | A single value of oral temperature 38.3°C or 38°C sustained for at least 1 hour according to Infectious Diseases Society of America (IDSA) guidelines |
| Quinolone prophylaxis [8] | According to IDSA guidelines, prophylactic therapy with ciprofloxacin or levofloxacin in the high-risk patients with profound neutropenia predicted for > 7 days was noted as quinolone prophylaxis. |
| Multidrug resistant bacteria infection [9,10] | An infection due to a Gram-negative bacteria which has a resistance to ≥ 3 classes of antimicrobial agents, and for Gram-positive bacteria, methicillin resistance for *Staphylococcus* and vancomycin resistance for *Enterococcus* |
| Inadequate initial antibiotic therapy [11] | Administered drug has no in vitro activity against the strain responsible for the infection according to antimicrobial susceptibility test results or administration of the drug after 48 hours of positive culture results |
| Prior antimicrobial therapy [11] | The use of antimicrobial within the last three months before the infection episode |
| Length of time to adequate antibiotic therapy | Length of time from positive culture results to the initiation of adequate antibiotic therapy |

(Bastug et al. – Emergence of MDR isolates in patients with cancer J Infect Dev Ctries 2015; 9(10):1100-1107.)

(ANTRH) in Turkey. The medical records of the
patients admitted to hemato-oncology wards of the
1,140-bed tertiary care hospital between 2008 and
2013 were investigated. The results of sterile site
cultures of patients with hemato-oncological
malignancies were analyzed. Clinical significance
(infection or colonization) of each positive culture was
assessed by an infectious disease specialist, and the
infections of the patients were defined according to the
Centers for Disease Control (CDC) definitions [6].
The patients with laboratory-confirmed BSIs and
urinary tract infections were included into the study.

Statistical analyses were based on the infection
episodes. A new infection episode was defined as
positive blood or urine culture meeting the CDC case
definition and at least seven afebrile intervening days
since the previous infection [7]. The patients were
divided in two groups, survivors and non-survivors,
according to the outcome on day 30 after each
infection onset. The demographic, clinical, and
laboratory characteristics of the two groups were
compared statistically and the impact of the risk
factors on mortality was defined. The effect of
fluoroquinolone prophylaxis on the acquisition of
infections with MDR isolates in 126 febrile
neutropenic episodes was also evaluated, since
quinolone prophylaxis was used in only high-risk
neutropenic patients.
**Statistical analysis**

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) version 20.0. Descriptive statistics are presented as mean, standard deviation, median, minimum, and maximum for quantitative variables, and as number and percentage for categorical variables. In numerical comparisons, when a normal distribution was provided, the Mann-Whitney U test was used for paired independent groups. In categorical comparisons, the Chi-square test was used for paired and multi-groups. For multi-group and paired group comparisons that did not meet the Chi-square requirement, Monte-Carlo simulation and Fisher’s exact test were used, respectively. Logistic regression analysis was used in the determination of risk factors for categorical variables. Statistical level of significance was set at p < 0.05.

**Results**

**Demographic and clinical characteristics of the patients**

During the six-year study period (2008–2013), a total of 205 infection episodes of 132 patients (43.2% males) were identified. Characteristics of the patients, infection episodes, and causative pathogens are listed in Tables 2, 3, and 4.

The mean age of the patients was 48.3 ± 15.5 years (16.7% were > 65 years of age). Of them, 75% had

---

**Table 2. Basal characteristics of the patients (n = 132)**

| Characteristics                                      | Number of patients n (%) | Survivors n = 96 | Non-survivors n = 36 | P value |
|------------------------------------------------------|--------------------------|------------------|----------------------|---------|
| Age (years, mean ± standard deviation [SD])         | 48.3 ± 15.5              | 47.59 ± 15.0     | 50.44 ± 16.9         | > 0.05  |
| Age > 65 years                                       | 22 (16.7)                | 12 (12.5)        | 10 (27.8)            | 0.03    |
| Gender (male)                                        | 57 (43.2)                | 54 (56.3)        | 21 (58.3)            | > 0.05  |
| Solid organ tumor                                    | 25 (18.9)                | 19 (19.8)        | 6 (16.7)             | > 0.05  |
| Hematologic malignancy                               | 107 (81.1)               | 77 (80.2)        | 30 (83.3)            | > 0.05  |
| Acute leukemia                                       | 62 (47.0)                | 42 (43.8)        | 20 (55.6)            | > 0.05  |
| Lymphoma                                             | 21 (15.9)                | 17 (17.7)        | 4 (11.1)             | > 0.05  |
| Multiple myeloma                                     | 16 (12.1)                | 15 (15.6)        | 1 (2.8)              | > 0.05  |
| Other hematologic malignancies                       | 8 (6.1)                  | 3 (3.1)          | 5 (13.9)             | > 0.05  |
| Prior HSCT                                           | 34 (25.8)                | 30 (31.3)        | 4 (11.1)             | 0.01    |
| Comorbidities                                        | 17 (12.9)                | 10 (10.4)        | 7 (19.4)             | > 0.05  |
| Diabetes mellitus                                    | 12 (9.1)                 | 7 (7.3)          | 5 (13.9)             | > 0.05  |
| COPD                                                 | 2 (1.5)                  | 0 (0.0)          | 2 (100.0)            | -       |
| Renal failure                                        | 8 (6.1)                  | 4 (4.2)          | 4 (11.1)             | > 0.05  |

HSCT: hematopoietic stem cell transplantation; COPD: chronic obstructive pulmonary disease

**Table 3. Characteristics of the infection episodes (n = 205)**

| Characteristics                                      | Number of episodes n (%) | Survivors n = 157 | Non-survivors n = 48 | P value |
|------------------------------------------------------|--------------------------|-------------------|----------------------|---------|
| Presence of CVC                                      | 106 (51.7)               | 80 (51.0)         | 26 (54.2)            | > 0.05  |
| Presence of mucositis                                | 30 (14.6)                | 25 (15.9)         | 5 (10.4)             | > 0.05  |
| Ongoing chemotherapy                                 | 150 (73.2)               | 115 (73.2)        | 35 (72.9)            | > 0.05  |
| Previous chemotherapy (within 3 months)             | 41 (20)                  | 33 (21.0)         | 8 (16.7)             | > 0.05  |
| Fluoroquinolone prophylaxis                          | 66 (32.2)                | 54 (34.4)         | 12 (25.0)            | > 0.05  |
| Prior antibiotic therapy                             | 118 (57.6)               | 86 (92.4)         | 32 (96.9)            | > 0.05  |
| Neutropenia (< 500 cells/mm³)                        | 126 (61.5)               | 91 (58.0)         | 34 (70.8)            | > 0.05  |
| Profound neutropenia (< 100 cells/mm³)              | 107 (52.2)               | 81 (51.6)         | 26 (54.2)            | > 0.05  |
| Prolonged neutropenia prior to infection (> 7 days)  | 59 (28.8)                | 37 (23.6)         | 22 (45.8)            | 0.003   |
| Duration of neutropenia (mean ± SD, days)           | 12.2 ± 17.0              | 11.7 ± 17.2       | 13.96 ± 16.3         | > 0.05  |
| Febrile neutropenia                                  | 126 (61.5)               | 92 (58.6)         | 34 (70.8)            | > 0.05  |

Site of infection:

| Characteristics                                      | Number of episodes n (%) | Survivors n = 157 | Non-survivors n = 48 | P value |
|------------------------------------------------------|--------------------------|-------------------|----------------------|---------|
| Bloodstream infection                                | 160 (78.0)               | 119 (75.8)        | 41 (85.4)            | > 0.05  |
| UTI                                                  | 45 (22.0)                | 38 (24.2)         | 7 (14.6)             | > 0.05  |
| Inadequate initial antimicrobial therapy              | 86 (42.0)                | 55 (35.0)         | 31 (64.6)            | < 0.001 |
| Length of time to adequate antimicrobial therapy (mean ± SD, days) | 1.6 ± 2.8               | 1.6 ± 2.9         | 1.3 ± 1.9            | > 0.05  |
| Length of time to infection (mean ± SD, days)        | 21.3 ± 17.2              | 20.3 ± 15.7       | 24.5 ± 21.1          | > 0.05  |

CVC: central venous catheter; UTI: urinary tract infection
hematologic malignancies (acute leukemia, 47%) and 25% had solid tumors. Thirty-four patients (25.8%) were hematopoietic stem cell transplantation (HSCT) recipients. Febrile neutropenia was detected in 61.5% (126/205) of all episodes. The mean length between hospital admission and emergence of infections was 21.35 ± 17.22 days. Polymicrobial infection was not detected. BSI was the most frequent infection (78%), followed by urinary tract infection (UTI).

**Characteristics of causative pathogens**

Regarding the isolated microorganisms, the majority of the pathogens were *Enterobacteriaceae* (44.3%, n = 91), followed by nonfermentative pathogens (17.6%, n = 36), Gram-positive cocci (30.2%, n = 62), and *Candida* species (7.8%, n = 16). The most frequently isolated pathogen was *Escherichia coli*, which was responsible for 29.2% of all infection episodes. The ESBL rate of the isolates was 36.6% (n = 75). MDR pathogens were isolated in 56.1% of the episodes (115/205 episodes). Of the total MDR infections, 16.1% (n = 33) were caused by Gram-positive isolates (vancomycin-resistant enterococcus, 1.5% [n = 3], methicillin-resistant staphylococcus, 14.6% [n = 30]), whereas 40% (n = 82) were caused by Gram-negative isolates. MDR rates were higher in *Klebsiella* spp. (13/23, 56.5%) and *Acinetobacter baumannii* (14/16, 87.5%). The antimicrobial resistance patterns of the isolates is summarized in Table 5.

**Table 4. Causative pathogens of 205 infection episodes**

| Causative pathogens                  | Total n (%) | Survivors n (%) | Non-survivors n (%) | P value |
|--------------------------------------|-------------|-----------------|---------------------|---------|
| Gram-negative bacteria               | 127 (62.0)  | 89 (56.7)       | 38 (79.2)           | 0.005   |
| *Escherichia coli*                   | 60 (29.3)   | 48 (30.6)       | 12 (25.0)           | > 0.05  |
| *Klebsiella* spp.                    | 23 (11.2)   | 12 (7.6)        | 11 (22.9)           | 0.003   |
| *Acinetobacter baumannii*            | 16 (7.8)    | 6 (3.8)         | 10 (20.8)           | < 0.001 |
| *Pseudomonas aeruginosa*             | 12 (5.9)    | 9 (5.7)         | 3 (6.3)             | > 0.05  |
| Other Gram-negative bacteria         | 16 (7.8)    | 14 (8.9)        | 2 (4.1)             | > 0.05  |
| Gram-positive bacteria               | 62 (30.2)   | 55 (35.0)       | 7 (14.6)            | 0.02    |
| *Coagulase negative staphylococci*  | 36 (17.6)   | 33 (21.0)       | 3 (6.3)             | 0.019   |
| *Enterococcus* spp.                  | 17 (8.3)    | 15 (9.6)        | 2 (4.2)             | > 0.05  |
| *Staphylococcus aureus*              | 8 (3.9)     | 6 (3.8)         | 2 (4.2)             | > 0.05  |
| *Streptococcus* spp.                 | 1 (0.48)    | 1 (0.6)         | 0 (0.0)             | -       |
| *Candida* spp.                       | 16 (7.8)    | 13 (8.3)        | 3 (6.3)             | > 0.05  |

**Table 5. Antimicrobial resistance patterns of the isolates of 205 infection episodes**

| Resistance pattern of isolates       | Total isolates n (%) | Survivors n (%) | Non-survivors n (%) | P value |
|--------------------------------------|----------------------|-----------------|---------------------|---------|
| ESBL (+) isolates                    | 75 (36.6)            | 49 (31.2)       | 26 (54.2)           | 0.004   |
| Gram-negative MDR isolates           | 82 (40)              | 54 (34.4)       | 28 (58.3)           | 0.003   |
| Gram-positive MDR isolates           | 33 (16.1)            | 28 (17.8)       | 5 (10.4)            | > 0.05  |

*ESBL: extended-spectrum beta lactamase; MDR: multidrug-resistant*
statistically significant risk factor for mortality (p = 0.005, OR = 2.65, 95% CI = 1.25–5.59). When the causative pathogens of the infections were evaluated for mortality, infections with *Klebsiella* spp. (OR = 3.75, 95% CI = 1.31–10.7, p = 0.013) and *A. baumannii* (OR = 5.00, 95% CI = 1.38–18.2, p = 0.014) were determined to be independent predictors of mortality. The rate of infections due to coagulase-negative *Staphylococcus* (CoNS) was found to be significantly higher in non-fatal cases (p = 0.019, OR = 0.25, 95% CI = 0.07–0.85). Mortality rates according to causative pathogens are summarized in Table 4.

**Mortality for ESBL and MDR pathogens**

ESBL-positive and MDR Gram-negative isolates were found significantly more frequently in the non-survivor group (26/48, 54.2%, p = 0.004 and 28/48, 58.3%, p = 0.003, respectively). There was no significant mortality difference between groups in terms of the rate of Gram-positive MDR isolate infections (Table 5).

**The effect of quinolone prophylaxis on the acquisition of infections with MDR isolates**

The analysis of 126 febrile neutropenic episodes showed no significant association between the use of quinolone prophylaxis and Gram-negative MDR infections. However, quinolone prophylaxis was significantly higher in infectious episodes with MDR Gram-positive isolates (78.3% versus 21.7%, p < 0.001, OR = 3.75, 95% CI = 1.31–10.7). Mortality rates according to causative pathogens are summarized in Table 4.

**Univariate and multivariate predictors of mortality**

When the risk factors for mortality were evaluated in univariate analysis, older age (> 65 years), inadequate initial antibiotic treatment, prolonged neutropenia (> 7 days) before infection, infections due to Gram-negative isolates (especially *Klebsiella* spp. and *A. baumannii*), and ESBL (+) and Gram-negative MDR (+) isolate infections were found to be significant risk factors for mortality. When the severity of neutropenia was evaluated in the infection episodes with prolonged neutropenia before infection onset, 86.4% of the cases had profound neutropenia, and mortality was significantly higher in this group (p = 0.047, OR = 2.94, 95% CI = 2.04–4.24). HSCT recipients and patients with Gram-positive isolate infections (especially with CoNS) had significantly lower mortality rates in univariate analysis (Tables 4–6).

Multivariate analysis showed that inadequate initial antibiotic treatment (OR = 4.04, 95% CI = 1.80–9.05, p = 0.001), prolonged neutropenia (> 7 days) before infection onset (OR = 3.61, 95% CI = 1.25–10.7, p = 0.013), and infection due to *Klebsiella* spp. (OR = 3.75, 95% CI = 1.31–10.7, p = 0.014) were independent predictors of mortality. HSCT recipients had a significantly lower mortality rate (OR = 0.30, 95% CI = 0.09–0.95, p = 0.041) (Table 6).

**Discussion**

Gram-negative bacteria infections have an increasing incidence in cancer patients. Recently, there have been alterations reported about the emergence of antimicrobial resistance to some Gram-negative isolates in patients with hematopoietic malignancies [14]. Until now, most of the studies in the literature have reported mortality risk factors or resistance patterns of isolates in BSIIs of neutropenic cancer patients. Appropriate antimicrobial therapy is very important in patients with hematopoietic malignancies, who are highly vulnerable to serious infections. Therefore, having information about the local distribution of pathogens and their antimicrobial resistance patterns is crucial in order to start proper

### Table 6. Univariate and multivariate predictors of mortality

| Variables                                    | Univariate analysis | Multivariate analysis |
|----------------------------------------------|---------------------|-----------------------|
|                                              | OR (95% CI)        | P value   | OR (95% CI)    | P value   |
| Age > 65 years                               | 2.69 (1.04–6.94)   | 0.036     | -              | > 0.05    |
| Prior HSCT                                   | 0.21 (0.07–0.64)   | 0.003     | 3.00 (0.90–9.50)| 0.041     |
| Prolonged neutropenia prior to infection (≥ 7 days) | 2.74 (1.39–5.40)   | 0.003     | 3.82 (1.53–9.47)| 0.004     |
| Inadequate initial antibiotic treatment      | 0.29 (0.15–0.58)   | <0.001    | 2.78 (1.24–6.26)| 0.013     |
| Gram-negative bacterial infection            | 2.65 (1.25–5.59)   | 0.005     | -              | > 0.05    |
| Infection with coagulase negative *Staphylococcus* | 0.25 (0.07–0.85)   | 0.019     | -              | > 0.05    |
| Infection with *Acinetobacter baumannii*.    | 6.62 (2.26–19.36)  | <0.001    | 5.00 (1.38–18.2)| 0.014     |
| Infection with *Klebsiella* spp.            | 3.59 (1.47–8.78)   | 0.003     | 3.75 (1.31–10.7)| 0.013     |
| Infection with ESBL-producing bacteria       | 0.49 (0.30–0.79)   | 0.004     | -              | > 0.05    |
| Infection with Gram-negative MDR bacteria    | 2.67 (1.37–5.17)   | 0.003     | -              | > 0.05    |

OR: odds ratio; CI: confidence interval; HSCT: hematopoietic stem cell transplantation; MDR: multidrug-resistant
empirical antibiotic therapy. The present study focused on the identification of the epidemiologic characteristics and antimicrobial resistance patterns (ESBL, MDR condition) of causative isolates from infections of cancer patients with or without neutropenia. Mortality risk factors in this group were also evaluated in the study. We determined the 30-day mortality rate as the main outcome measure; the mortality rate was 23.4% in 205 infection episodes of 132 patients. BSI was the most frequently detected infection (78%), followed by urinary tract infection. The type of infection was determined as statistically insignificant with regard to mortality. The microorganisms most frequently isolated in our study were Gram-negative bacteria; this result was consistent with the literature [15]. The predominant pathogen was E. coli (29.2%), followed by Klebsiella spp., A. baumannii, and Pseudomonas aeruginosa. Consistent with the findings of Chong et al., CoNS was the most common isolate among the Gram-positive bacteria [16]. Previous studies have indicated that Gram-negative BSIs had higher mortality rates than Gram-positive infections [17,18]. The early appropriate treatment of Gram-positive isolates (such as CoNS) is possible by quick and easy isolation of these pathogens, which explains the lower mortality for infection with these microorganisms [17]. In accordance with the literature, infections with Gram-negative isolates had significantly higher and Gram-positive isolates had lower mortality rates in our study as well. We thought that the low virulence of CoNS isolates may also cause the lower mortality in bacteremic patients. When the impact of isolated pathogens on mortality was evaluated, etiological agents were found to be statistically different between fatal and non-fatal cases. Infections with A. baumannii and Klebsiella spp. were found independent predictors of mortality. Klebsiella spp. and A. baumannii isolates were usually resistant to most of the antimicrobial agents used empirically. Thus, the initial antimicrobial therapy was inappropriate for most A. baumannii and Klebsiella spp. infections. We thought that this resistance pattern and the invasive characteristics of the A. baumannii isolates had an impact on increased mortality.

Increasing incidences of BSIs with MDR Gram-negative strains as well as MDR Gram-positive strains among patients with malignancies have been recently reported. Since BSIs is associated with higher morbidity and mortality, it is important to know local epidemiology and resistance patterns of causative isolates [14,15]. Various studies have reported adverse effects of antimicrobial resistant Gram-negative infections on mortality in cancer patients with BSIs [5,14,18]. In our study, Gram-negative MDR isolates were responsible for 40%, whereas Gram-positive MDR isolates were responsible for 16.1% of all infection episodes. Similar to the findings of Rosa et al., methicillin resistance and the production of ESBL were the most commonly encountered resistance patterns of infectious agents in our study [10]. Although it was assessed widely in many studies, a clear relationship between fluoroquinolone prophylaxis and antibiotic resistance has not been demonstrated to date [14,19,20]. Since it was used in high-risk neutropenic cancer patients, we evaluated the effect of fluoroquinolone prophylaxis on the acquisition of MDR isolate infections in 126 febrile neutropenic episodes. Subgroup analysis showed no significant association between the use of quinolone prophylaxis and acquisition of Gram-negative MDR infections. However, the use of quinolone prophylaxis was significantly higher in infections with MDR Gram-positive isolates of the febrile neutropenic patients.

Unlike Gram-positive MDR isolate infections, the mortality rate was found to be significantly higher in Gram-negative MDR strain infections in the present study. Moreover, inadequate initial antibiotic treatment was determined to be an independent risk factor for mortality, similar to previous studies [15,21]. Since the multidrug resistance pattern reduces the number of effective antibiotic options, it is frequently associated with inadequate initial antibiotic therapy and poor outcome [14]. In addition to adequate empirical antimicrobial therapy, the status of host defenses also plays an important role in patient outcome. Poor outcomes of neutropenic patients with acute leukemia showed the importance of neutrophils in survival from Gram-negative sepsis [22]. It has also been reported that the severity of neutropenia has an impact on survival [23]. In the present study, prolonged neutropenia prior to the onset of infection was found to be an independent predictor of mortality. It is likely to be associated with profound neutropenia. It was observed in the present study that prolonged and profound neutropenia before infection onset has a statistically significant impact on mortality. In our study, HSCT recipients with infections had a significantly lower mortality rate than did other infected patients. We thought that this was due to improved physical conditions of HSCT units, including HEPA-filtered single rooms, higher compliance rates of the healthcare professionals to the
strict contact precautions, and lower rates of infections due to MDR isolates compared to hemato-oncology units.

Conclusions
Infections due to the Gram-negative isolates were found to be predominant in patients with hemato-oncological malignancies. The emergence of MDR isolates should be taken into account before starting empirical antibiotherapy, which is crucial in these high-risk patients. Because of the importance of appropriate empirical therapy to survival, it is becoming a clinical challenge to overcome infections in patients with hemato-oncological malignancies. Therefore, an empiric antimicrobial therapy protocol for hemato-oncology units according to local surveillance data of the hospital is crucial.

References
1. Passerini R, Ghezzi TL, Sandri MT, Radice D, Biffi R (2011) Ten- year surveillance of nosocomial bloodstream infections; trends of aetiology and antimicrobial resistance in a comprehensive cancer centre. Ercancermedicascience 5: 191.
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317.
3. Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, Hsuueh PR (2010) Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect 138: 1044-1051.
4. Mediani M, Bagheri A, Khorvash F (2013) A Population Based Study of Bacterial Spectrum in Febrile Neutropenic Patients. Jundishapur J Microbiol 6: 150-156.
5. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J (2011) Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66: 657-663.
6. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332.
7. Poon LM, Jin J, Chee YL, Ding Y, Lee YM, Chng WI, Chai LY, Tan JK, Hsu LY (2012) Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. Singapore Med J 53: 720-725.
8. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, ItoJI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52: e56-e93.
9. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281.
10. Rosa RG, Luciano Z, Goldani MD, Santos RP (2014) Risk factors for multidrug-resistant bacteremia in hospitalized cancer patients with febrile neutropenia: A cohort study. Am J Infect Control 42: 74-76.
11. Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Ciusolo P, Fadda G, Leone G, Cauda R, Pagano L (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58: 299-307.
12. Clinical and Laboratory Standards Institute (2009) Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Eighth Edition: Approved Standard M07-A8. CLSI: Wayne, PA, USA.
13. Clinical and Laboratory Standards Institute (2010) Performance Standards for Antimicrobial Susceptibility
Testing: Twentieth Informational Supplement M100-S20. CLSI: Wayne, PA, USA.

14. Trecarichi EM, Tumbarello M (2014) Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis 27: 200-210.

15. Montassier E, Batard E, Gastinne T, Potel G, de La Cochetière MF (2013) Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 32: 841-850.

16. Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15: e277-e281.

17. Horasan ES, Ersoz G, Tombak A, Tiftik N, Kaya A (2011) Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients. Med Sci Monit 17: 304-309.

18. Tumbarello M, Spanu T, Caia M, Trecarichi EM, Laurenti L, Montuori E, Fianchi L, Leone F, Fadda G, Cauda R, Pagano L (2009) Factors associated with mortality in bacteremic patients with hematologic malignancies. Diagn Microbiol Infect Dis 64: 320-326.

19. Bow EJ (2011) Fluoroquinolones antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24: 545-553.

20. Gafter-Gvili A, Paul M, Frauser A, Leibovici L (2007) Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59: 5-22.

21. Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC (2007) Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51: 3510-3515.

22. Satlin MJ, Calfee DP, Chen L, Fauntleroy KA, Wilson SJ, Jenkins SG, Feldman EM, Roboz GJ, Shore TB, Helfgott DC, Soave R, Kreiswirth BN, Walsh TJ (2013) Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 54: 799-806.

23. Tumbarello M, Trecarichi EM, Caia M, Candoni A, Pastore D, Cattaneo C, Fanci R, Nosari A, Spadea A, Busca A, Vianelli N, Spanu T, Pagano L; He.M.A.B.I.S. (Hematological Malignancies Associated Bacterial Infections Surveillance) Italy (2012) Derivation and validation of a scoring system to identify patients with bacteremia and hematological malignancies at higher risk for mortality. PLoS One 7: e51612.

**Corresponding author**
Aliye Bastug
Department of Infectious Diseases and Clinical Microbiology
Ankara Numune Research and Training Hospital
Talatpasa Bulvari, Altindag/Ankara, Turkey
Phone: 05056814223
Fax: 0312 508 4838
Email: dr.aliye@yahoo.com

**Conflict of interests:** No conflict of interests is declared.